Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC.ALXN · Entity 137086 | EVP. Global Operations | February 28, 2018 | March 02, 2018 |
| DBV Technologies S.A.DBVT · Entity 5096 | Director | January 01, 2021 | January 11, 2021 |
| HOOKIPA Pharma Inc.HOOK · Entity 15295 | Director | June 17, 2024 | June 18, 2024 |
| ICON PLCICLR · Entity 3439 | Director | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALEXION PHARMACEUTICALS, INC.
Report date February 28, 2018 · Filed March 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 51,727 |
Reported balance
After 2018-02-28 transaction · row 1
1 source rowRow 1 · 2018-02-28 · Grant · Acquired 8,940 · Balance 51,727 F1: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date.
DBV Technologies S.A.
Report date January 01, 2021 · Filed January 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $72.22 · Expires 2027-06-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-01-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.223 to EURO 1.00 as of December 31, 2020. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $45.54 · Expires 2028-02-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.223 to EURO 1.00 as of December 31, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.223 to EURO 1.00 as of December 31, 2020.
HOOKIPA Pharma Inc.
Report date June 17, 2024 · Filed June 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2034-06-17 | Direct | 49,000 |
Reported balance
After 2024-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 49,000 · Balance 49,000 F1: This option award shall vest and become fully exercisable on the earlier to occur of (a) June 17, 2025 and (b) the date of the Issuer's next annual meeting of its stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option award shall vest and become fully exercisable on the earlier to occur of (a) June 17, 2025 and (b) the date of the Issuer's next annual meeting of its stockholders.
ICON PLC
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 3,515 |
Ending reported balance
After 2026-08-11 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-08-10 · Exercise / conversion · Acquired 1,732 · Balance 4,430 F1: These restricted share units were granted on May 22, 2025 and vested on August 10, 2026. F2: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting. Row 2 · 2026-08-11 · Sale · Disposed 95 · Balance 4,335 F3: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $162.08 to $163.0799, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Row 3 · 2026-08-11 · Sale · Disposed 105 · Balance 4,230 F3: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $163.15 to $164.1499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Row 4 · 2026-08-11 · Sale · Disposed 642 · Balance 3,588 F3: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $164.16 to $165.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Row 5 · 2026-08-11 · Sale · Disposed 73 · Balance 3,515 F3: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $165.16 to $166.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-10 · Exercise / conversion · Disposed 1,732 · Balance 0 F2: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting. F1: These restricted share units were granted on May 22, 2025 and vested on August 10, 2026. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 1,324 |
Reported balance
After 2026-08-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-10 · Grant · Acquired 1,324 · Balance 1,324 F2: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting. F8: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted share units were granted on May 22, 2025 and vested on August 10, 2026.
F2: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting.
F3: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $162.08 to $163.0799, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $163.15 to $164.1499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $164.16 to $165.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $165.16 to $166.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
F8: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2026 Filed Aug 12, 2026 21:01 UTC | ICON PLC ICLR · Entity 3439 | SaleOrdinary Shares | 73 | $165.51 | $12,082.23 |
DisclosureSEC source: 0001628280-26-056327 · wk-form4_1786568513.xml · nonDerivative · entry 5 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,515 F3 · kind: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $165.16 to $166.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 21:01 UTC | ICON PLC ICLR · Entity 3439 | SaleOrdinary Shares | 642 | $164.47 | $105,589.74 |
DisclosureSEC source: 0001628280-26-056327 · wk-form4_1786568513.xml · nonDerivative · entry 4 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,588 F3 · kind: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $164.16 to $165.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 21:01 UTC | ICON PLC ICLR · Entity 3439 | SaleOrdinary Shares | 105 | $163.77 | $17,195.85 |
DisclosureSEC source: 0001628280-26-056327 · wk-form4_1786568513.xml · nonDerivative · entry 3 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,230 F3 · kind: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $163.15 to $164.1499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 21:01 UTC | ICON PLC ICLR · Entity 3439 | SaleOrdinary Shares | 95 | $162.72 | $15,458.40 |
DisclosureSEC source: 0001628280-26-056327 · wk-form4_1786568513.xml · nonDerivative · entry 2 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,335 F3 · kind: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $162.08 to $163.0799, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:01 UTC | ICON PLC ICLR · Entity 3439 | GrantRestricted Share Units · Derivative | 1,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-056327 · wk-form4_1786568513.xml · derivative · entry 7 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,324 Underlying: Ordinary Shares · 1,324 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting. F8 · derivative.exercise_date: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027. F8 · derivative.expiration_date: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027. F8 · derivative.underlying: These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:01 UTC | ICON PLC ICLR · Entity 3439 | Exercise / conversionRestricted Share Units · Derivative | 1,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-056327 · wk-form4_1786568513.xml · derivative · entry 6 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,732 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting. F1 · derivative.exercise_date: These restricted share units were granted on May 22, 2025 and vested on August 10, 2026. F1 · derivative.expiration_date: These restricted share units were granted on May 22, 2025 and vested on August 10, 2026. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:01 UTC | ICON PLC ICLR · Entity 3439 | Exercise / conversionOrdinary Shares | 1,732 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-056327 · wk-form4_1786568513.xml · nonDerivative · entry 1 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These restricted share units were granted on May 22, 2025 and vested on August 10, 2026. F2 · price: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting. Read SEC document |
| June 17, 2024 Filed Jun 18, 2024 20:15 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 49,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001415889-24-017387 · form4-06182024_040609.xml · derivative · entry 1 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Stock · 49,000 shares Expires 2034-06-17 F1 · derivative.exercise_date: This option award shall vest and become fully exercisable on the earlier to occur of (a) June 17, 2025 and (b) the date of the Issuer's next annual meeting of its stockholders. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 21:15 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-23-070002 · tm2318326-4_4seq.xml · derivative · entry 1 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-06-09 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier to occur of (a) June 9, 2024 and (b) the date of the Issuer's 2024 annual meeting of its stockholders. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:12 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001104659-22-076830 · tm2220275-8_4seq1.xml · derivative · entry 1 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-30 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on June 30, 2023. Read SEC document |
| June 01, 2021 Filed Jun 5, 2021 00:36 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 9,600 | $0.00 Strike: $16.61 | $0.00 |
DisclosureSEC source: 0001104659-21-077248 · tm2118388d4_4seq1.xml · derivative · entry 1 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 9,600 shares Expires 2031-06-01 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on June 1, 2022. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 20:03 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantCommon Stock | 4,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-117708 · a4.xml · nonDerivative · entry 1 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,969 Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:27 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 9,600 | $0.00 Strike: $11.45 | $0.00 |
DisclosureSEC source: 0001104659-20-075253 · a4.xml · derivative · entry 1 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 9,600 shares Expires 2030-06-18 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on June 18, 2021. Read SEC document |
| December 18, 2019 Filed Jan 3, 2020 21:04 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 9,600 | $0.00 Strike: $9.96 | $0.00 |
DisclosureSEC source: 0001104659-20-000852 · a4.xml · derivative · entry 1 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 9,600 shares Expires 2029-12-18 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on December 18, 2020. Read SEC document |
| April 17, 2019 Filed Apr 24, 2019 21:33 UTC | HOOKIPA Pharma Inc. HOOK · Entity 15295 | GrantStock Option (Right to Buy) · Derivative | 6,924 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001104659-19-023454 · a4.xml · derivative · entry 1 O'Neill Julie · CIK 0001630299 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,924 Underlying: Common Stock · 6,924 shares Expires 2029-04-17 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on April 17, 2020, with the remainder vesting in 8 equal quarterly installments thereafter. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 17:25 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 686 | $118.61 | $81,366.46 |
DisclosureSEC source: 0000899866-18-000048 · wf-form4_151994310701630.xml · nonDerivative · entry 2 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,787 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 16:59 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 8,940 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-18-000057 · wf-form4_152002796986423.xml · nonDerivative · entry 1 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,727 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 17:25 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 939 | $120.72 | $113,356.08 |
DisclosureSEC source: 0000899866-18-000048 · wf-form4_151994310701630.xml · nonDerivative · entry 1 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,473 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| February 08, 2018 Filed Feb 8, 2018 19:16 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 4,787 | $116.31 | $556,775.97 |
DisclosureSEC source: 0000899866-18-000038 · wf-form4_151813538670414.xml · nonDerivative · entry 3 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,412 F3 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $116.00 - $116.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 19:16 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-18-000038 · wf-form4_151813538670414.xml · nonDerivative · entry 2 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,199 F2 · shares: On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 7,500 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/4 of such shares vested on February 6, 2018 and 1/4 vest on each subsequent anniversary. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 19:16 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 21,489 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-18-000038 · wf-form4_151813538670414.xml · nonDerivative · entry 1 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,699 F1 · shares: On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 21,489 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/3 of such shares vested on February 6, 2018 and 1/3 vest on each subsequent anniversary. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 18:35 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 2,119 | $117.26 | $248,473.94 |
DisclosureSEC source: 0000899866-18-000014 · wf-form4_151804651266221.xml · nonDerivative · entry 1 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,210 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| September 05, 2017 Filed Sep 5, 2017 19:28 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 650 | $145.81 | $94,776.50 |
DisclosureSEC source: 0000899866-17-000161 · wf-form4_150465408293648.xml · nonDerivative · entry 5 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,329 F4 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| September 05, 2017 Filed Sep 5, 2017 19:28 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 600 | $145.64 | $87,384.00 |
DisclosureSEC source: 0000899866-17-000161 · wf-form4_150465408293648.xml · nonDerivative · entry 4 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,979 F1 · shares: The transaction is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $145.51 - $146.51. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| September 05, 2017 Filed Sep 5, 2017 19:28 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 672 | $147.00 | $98,784.00 |
DisclosureSEC source: 0000899866-17-000161 · wf-form4_150465408293648.xml · nonDerivative · entry 3 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,579 F1 · shares: The transaction is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. Read SEC document |
| September 05, 2017 Filed Sep 5, 2017 19:28 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 1,841 | $145.81 | $268,436.21 |
DisclosureSEC source: 0000899866-17-000161 · wf-form4_150465408293648.xml · nonDerivative · entry 2 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,251 F1 · shares: The transaction is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:28 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 612 | $142.00 | $86,904.00 |
DisclosureSEC source: 0000899866-17-000161 · wf-form4_150465408293648.xml · nonDerivative · entry 1 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,092 F1 · shares: The transaction is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $142.00 - $142.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| August 28, 2017 Filed Aug 30, 2017 18:13 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 11,160 | $140.00 | $1,562,400.00 |
DisclosureSEC source: 0000899866-17-000157 · wf-form4_150413117771204.xml · nonDerivative · entry 1 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,704 F1 · shares: The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 18:03 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 651 | $133.80 | $87,103.80 |
DisclosureSEC source: 0000899866-17-000066 · wf-form4_148884139522721.xml · nonDerivative · entry 1 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,864 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $133.00 - $133.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 19:46 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantOption to Purchase Common Stock · Derivative | 14,800 | $0.00 Strike: $131.25 | $0.00 |
DisclosureSEC source: 0000899866-17-000059 · wf-form4_148841554965881.xml · derivative · entry 4 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,800 Underlying: Common Stock, par value $.0001 per share · 14,800 shares Expires 2027-02-28 F4 · shares: Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 19:46 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-17-000059 · wf-form4_148841554965881.xml · nonDerivative · entry 3 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,515 F3 · shares: Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 19:46 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 664 | $131.70 | $87,448.80 |
DisclosureSEC source: 0000899866-17-000059 · wf-form4_148841554965881.xml · nonDerivative · entry 2 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,015 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 19:46 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 910 | $131.20 | $119,392.00 |
DisclosureSEC source: 0000899866-17-000059 · wf-form4_148841554965881.xml · nonDerivative · entry 1 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,679 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 16:40 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 2,795 | $125.69 | $351,303.55 |
DisclosureSEC source: 0000899866-17-000030 · wf-form4_148659002434774.xml · nonDerivative · entry 1 O'Neill Julie · CIK 0001630299 · EVP. Global Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,589 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $125.00 - $125.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.